Physician profile
Amy Colcher
NPI 1174554901
$919.73
in general payments reported to CMS, 2019-2025
14 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $14.45 · 2021: $14.33 · 2022: $17.97 · 2024: $173 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $322.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $143.84 | 2019-2025 | |
| Allergan, INC. | $139.08 | 2019-2020 | |
| Merz Pharmaceuticals, LLC | $124.88 | 2024 | Xeomin |
| Celgene Corporation | $96.99 | 2019 | |
| Sunovion Pharmaceuticals INC. | $94.71 | 2019 | |
| Acadia Pharmaceuticals INC | $56.48 | 2019 | |
| Acorda Therapeutics, INC | $51.75 | 2019 | |
| Amgen INC. | $51.19 | 2019-2025 | Uplizna |
| Lundbeck LLC | $43.37 | 2019 | |
| Pfizer INC. | $42.86 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $30.27 | 2019-2024 | Austedo Xr |
| Mdd US Operations, LLC | $18.88 | 2025 | |
| Biogen, INC. | $13.07 | 2019 | |
| Aquestive Therapeutics, INC. | $12.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Colcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.